WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO" or "Offering"); and/or (b) between September 18, 2020 and June 17, 2021, both dates inclusive (the "Class Period"), of the important August 24, 2021lead plaintiff deadline.
SO WHAT: If you purchased Athira securities pursuant and/or traceable to the Company's IPO and/or during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Athira class action, go to http://www.rosenlegal.com/cases-register-2111.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 24, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuits, the Offering documents contained and defendants made false and/or misleading statements and/or failed to disclose that: (1) the research conducted by the Company's Chief Executive Officer and President, Leen Kawas, was tainted by Kawas' scientific misconduct, including the manipulation of key data through the altering of Western blot images; (2) this purported research was foundational to Athira's efforts to develop treatments for Alzheimer's because it laid the biological groundwork that Athira was using in its approach to treating Alzheimer's; (3) as a result, Athira's intellectual property and product development for the treatment of Alzheimer's was based on invalid research; and (4) as a result of the foregoing, defendants' positive statements about Athira's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.